Want to see BBIO full AI Analyst Report?
BBIO Stock Chart & Stats
$76.75
-$0.10(-0.35%)
At close: 4:00 PM EST
$76.75
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$42.09 - $93.42
Previous CloseN/A
Volume379.31K
Average Volume (3M)4.10M
Market Cap
$15.74B
Enterprise Value$16.92K
Total Cash (Recent Filing)$940.19M
Total Debt (Recent Filing)$3.38B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Jul 30, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding196,036,790
10 Day Avg. Volume4,584,711
30 Day Avg. Volume4,096,106
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$107.39Price Target Upside39.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$964.88M
Bulls Say, Bears Say
Bulls Say
Rapid Atruvio Revenue GrowthSustained, large QoQ and YoY Atruvio growth demonstrates durable commercial traction and expanding patient uptake. This revenue base can fund scale, enable operating leverage as fixed costs are spread, and underpins management's path to breakeven while supporting launches of additional pipeline assets.
Very High Gross Margins (~95%)A ~95% gross margin signals strong unit economics for product sales in ATTR and related specialty medicines. High gross margins create a durable buffer to absorb SG&A and R&D spending, improving the company’s ability to translate higher sales into operating leverage and eventual profitability over time.
Strengthened Capital Runway Via FinancingThe large preferred equity raise materially improves liquidity and reduces near-term refinancing risk, providing permanent capital to fund commercialization and multiple planned launches. This structural funding supports execution of the commercial strategy and lowers the immediacy of dilution from near-term equity raises.
Bears Say
Large Ongoing Cash Burn And Negative FCFPersistent negative operating and free cash flow indicate the business remains cash‑consumptive absent sustained commercial scale. Continued burn elevates dependency on external financing, risks dilution, and constrains discretionary investment if revenues slow or launch costs run higher than planned.
Negative Stockholders' EquityA sizable negative equity balance reflects accumulated losses and weak capital buffer, reducing financial flexibility. Over time this increases refinancing and covenant risk, may limit partner or payer confidence, and can force suboptimal financing choices if operational performance falters.
Revenue Concentrated In One ProductHeavy dependence on a single commercial product concentrates execution and access risk: payer decisions, diagnostic bottlenecks, or competitive entrants could materially affect revenues. Durable risk remains until additional pipeline approvals and launches materially diversify the revenue base.
BridgeBio Pharma News
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $42.09 and its highest was $93.42 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $15.74B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Jul 30, 2026 which is in 12 days.
How were Bridgebio Pharma’s earnings last quarter?
Bridgebio Pharma released its earnings results on May 07, 2026. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.679 by -$0.161.
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate is -0.58.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 196,036,790 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Bridgebio Pharma reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.679. Following the earnings report the stock price went down -0.089%.
Which hedge fund is a major shareholder of Bridgebio Pharma?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.39 (39.92% Upside)
$107.39 (39.92% Upside)
Blogger Sentiment
Neutral
BBIO Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.48%
12-Months-Change
Fundamentals
Return on Equity
36.00%
Trailing 12-Months
Asset Growth
55.50%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
BBIO Stock 12 Month Forecast
Average Price Target
$107.39
▲(39.92% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
3.95% Insiders
26.93% Mutual Funds
0.12% Other Institutional Investors
56.42% Public Companies and
Individual Investors